News

Filter

1 to 9 of 17 results

Mylan 4th-qtr 2013 adjusted diluted EPS increases 20%, beating expectations

27-02-2014

US generics major Mylan reported financial results for the fourth-quarter and full year 2013, showing…

FinancialGenericsMylan Laboratories

Teva denies claims its MS drug Copaxone profits set to slump

Teva denies claims its MS drug Copaxone profits set to slump

25-11-2013

Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, this morning strongly…

CopaxoneEuropeFinancialMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

Mylan's 2nd-qtr misses consensus on sales but beats on EPS

01-08-2013

US generics drugmaker Mylan (Nasdaq: MYL) announced its financial results for the second quarter of 2013,…

FinancialGenericsMylan Laboratories

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Mylan settles Provigil litigation with Teva

10-06-2012

US generic major Mylan (Nasdaq: MYL) says that its subsidiary Mylan Pharmaceuticals has resolved all…

CephalonFinancialGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaProvigilTeva Pharmaceutical Industries

News briefs: Genmab/GSK, Gilead and Mylan

24-05-2012

Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4…

Anti-viralsBiotechnologycobicistatFinancialGenericsGenmabGilead SciencesGlaxoSmithKlineMylan LaboratoriesOncologyRegulationViramune

1 to 9 of 17 results

COMPANY SPOTLIGHT

Menarini

Back to top